jean-christophe_tellier_ucb_ceo

UCB’s new chief executive picked as EU rep for MISG

pharmafile | February 25, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Jean-Christophe Tellier, MISG, UCB 

UCB’s newly-appointed chief executive Jean-Christophe Tellier has been selected to join the Ministerial Industry Strategy Group (MISG).

Elected to the MISG by members of the European Medicines Group (EMG), Tellier will act as group representative for European pharma companies.

Co-chaired by the secretary of state for health and the chairman of the British pharma group, the MISG was set up so government and industry can work together on advancing the bio-pharma environment in the UK, and support research.

Advertisement

On his appointment, Tellier explains: “The UK life sciences industry is one of the most successful at a global level and it is an important contributor to the country’s economic prosperity. Therefore, I am pleased to be sharing some of UCB’s experience as an inward R&D inward investor with the MISG, in an effort to shape a positive climate that incentivises innovation for the improvement of patient care.”

Tellier joined UCB in 2011 as an executive vice president, after serving as the president of Ipsen, North America and chief executive of Novartis Pharma France. 

Related Content

UCB presents positive results for fenfluramine in CDKL5 deficiency disorder

UCB has announced positive results from its phase 3 GEMZ study, showing that fenfluramine can …

UCB announces first-in-patient trial success for galvokimig in atopic dermatitis

UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …

Rare and severe epilepsies – current treatments and advance therapeutics

The current forms of immunotherapy, how T cell therapy works and what the future holds

The Gateway to Local Adoption Series

Latest content